Literature DB >> 20842444

Apolipoprotein A1 -75 G/A and +83 C/T polymorphisms: susceptibility and prognostic implications in breast cancer.

Bechr Hamrita1, Hela Ben Nasr, Sallouha Gabbouj, Noureddine Bouaouina, Lotfi Chouchane, Karim Chahed.   

Abstract

Apolipoprotein A1 (ApoA1) is the major apoprotein constituent of high-density lipoprotein that can play important roles in tumor invasion and metastasis. In the current report, we evaluated the role of the functional ApoA1 polymorphisms (-75 G/A and +83 C/T) as genetic markers for breast cancer susceptibility and prognosis. We used the polymerase chain reaction and restriction enzyme digestion (RFLP-PCR) to characterize the variations of the ApoA1 gene in 295 unrelated Tunisian patients with breast carcinoma and 197 healthy control subjects. No association was found between the +83 C/T genetic variation in ApoA1 gene and the risk of breast cancer occurrence. The presence of the (+83) T allele appeared however to be associated with an increased risk of lymph node metastasis occurrence (OR = 2.94; P = 0.01). Furthermore, a positive association was found between ApoA1 -75 A allele carriers and breast cancer risk (OR = 1.57; P = 0.02). Regarding prognostic indicators, a significant association was found between ApoA1 (-75) A allele carriers and the premenopausal status of breast cancer patients (OR = 1.73; P = 0.03). Additionally, the presence of the -75 A allele was correlated with the oestrogen receptor status among premenopausal women (OR = 2.45; P = 0.02). This is the first report on the studies of ApoA1 single nucleotide polymorphisms (SNPs) in breast carcinomas. Our data suggest that these genetic variations of ApoA1 may represent a marker for the increased risk of breast cancer.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20842444     DOI: 10.1007/s11033-010-0274-0

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  24 in total

1.  HLA-DR typing by PCR amplification with sequence-specific primers (PCR-SSP) in 2 hours: an alternative to serological DR typing in clinical practice including donor-recipient matching in cadaveric transplantation.

Authors:  O Olerup; H Zetterquist
Journal:  Tissue Antigens       Date:  1992-05

2.  Apolipoprotein A-I inhibits the production of interleukin-1beta and tumor necrosis factor-alpha by blocking contact-mediated activation of monocytes by T lymphocytes.

Authors:  N Hyka; J M Dayer; C Modoux; T Kohno; C K Edwards; P Roux-Lombard; D Burger
Journal:  Blood       Date:  2001-04-15       Impact factor: 22.113

3.  Tumor recognition following Vgamma9Vdelta2 T cell receptor interactions with a surface F1-ATPase-related structure and apolipoprotein A-I.

Authors:  Emmanuel Scotet; Laurent O Martinez; Ethan Grant; Ronald Barbaras; Paul Jenö; Martine Guiraud; Bernard Monsarrat; Xavier Saulquin; Sophie Maillet; Jean-Pierre Estève; Frédéric Lopez; Bertrand Perret; Xavier Collet; Marc Bonneville; Eric Champagne
Journal:  Immunity       Date:  2005-01       Impact factor: 31.745

Review 4.  High-density lipoprotein and the acute phase response.

Authors:  Anisa Jahangiri
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2010-04       Impact factor: 3.243

5.  Transcription efficiency of human apolipoprotein A-I promoter varies with naturally occurring A to G transition.

Authors:  R Tuteja; N Tuteja; C Melo; G Casari; F E Baralle
Journal:  FEBS Lett       Date:  1992-06-08       Impact factor: 4.124

6.  Aromatase activity and expression in breast cancer and benign breast tissue stromal cells.

Authors:  S J Santner; R J Pauley; L Tait; J Kaseta; R J Santen
Journal:  J Clin Endocrinol Metab       Date:  1997-01       Impact factor: 5.958

7.  Validation of serum biomarkers for detection of early-stage ovarian cancer.

Authors:  Vladimir Nosov; Feng Su; Malaika Amneus; Michael Birrer; Terry Robins; Jenny Kotlerman; Srinivasa Reddy; Robin Farias-Eisner
Journal:  Am J Obstet Gynecol       Date:  2009-03-14       Impact factor: 8.661

8.  A CYP19 (aromatase) polymorphism is associated with increased premenopausal breast cancer risk.

Authors:  Kathryn E Talbott; Marilie D Gammon; Muhammad G Kibriya; Yu Chen; Susan L Teitelbaum; Chang-Min Long; Irina Gurvich; Regina M Santella; Habibul Ahsan
Journal:  Breast Cancer Res Treat       Date:  2007-11-02       Impact factor: 4.872

9.  Inhibition of apolipoprotein AI gene expression by tumor necrosis factor alpha: roles for MEK/ERK and JNK signaling.

Authors:  Ann Beers; Michael J Haas; Norman C W Wong; Arshag D Mooradian
Journal:  Biochemistry       Date:  2006-02-21       Impact factor: 3.162

10.  ProApolipoprotein A1: a serum marker of brain metastases in lung cancer patients.

Authors:  Nicola Marchi; Peter Mazzone; Vincent Fazio; Tarek Mekhail; Thomas Masaryk; Damir Janigro
Journal:  Cancer       Date:  2008-03-15       Impact factor: 6.860

View more
  13 in total

1.  Association of gene polymorphisms in prolactin and its receptor with breast cancer risk in Taiwanese women.

Authors:  Fan-Yun Mong; Yu-Liang Kuo; Ching-Wen Liu; Wen-Sheng Liu; Li-Ching Chang
Journal:  Mol Biol Rep       Date:  2010-12-02       Impact factor: 2.316

2.  Identifying grade/stage-related active modules in human co-regulatory networks: a case study for breast cancer.

Authors:  Chenchen Feng; Lina Chen; Wan Li; Hong Wang; Liangcai Zhang; Xu Jia; Zhengqiang Miao; Xiaoli Qu; Weiguo Li; Weiming He
Journal:  OMICS       Date:  2012-12

3.  Effect of apolipoprotein A1 genetic polymorphisms on lipid profiles and the risk of coronary artery disease.

Authors:  BiHong Liao; KeQi Cheng; ShaoHong Dong; HuaDong Liu; ZhengLei Xu
Journal:  Diagn Pathol       Date:  2015-07-16       Impact factor: 2.644

4.  The dyslipidemia-associated SNP on the APOA1/C3/A5 gene cluster predicts post-surgery poor outcome in Taiwanese breast cancer patients: a 10-year follow-up study.

Authors:  Mei-Chi Hsu; Kuo-Ting Lee; Wei-Chiang Hsiao; Chih-Hsing Wu; Hung-Yu Sun; I-Ling Lin; Kung-Chia Young
Journal:  BMC Cancer       Date:  2013-07-05       Impact factor: 4.430

5.  Association of apolipoprotein A1 -75 G/A polymorphism with susceptibility to the development of acute lung injury after cardiopulmonary bypass surgery.

Authors:  Jie Tu; Bingdong Zhang; Yanhua Chen; Beiwei Liang; Dongke Liang; Guofeng Liu; Fang He
Journal:  Lipids Health Dis       Date:  2013-11-11       Impact factor: 3.876

6.  Identification of Differentially Expressed Proteins in the Serum of Colorectal Cancer Patients Using 2D-DIGE Proteomics Analysis.

Authors:  Lay Cheng Lim; Mee Lee Looi; Syed Zulkifli Syed Zakaria; Ismail Sagap; Isa Mohammed Rose; Siok-Fong Chin; Rahman Jamal
Journal:  Pathol Oncol Res       Date:  2016-01       Impact factor: 3.201

7.  Identification of High Serum Apolipoprotein A1 as a Favorable Prognostic Indicator in Patients with Multiple Myeloma.

Authors:  Lifan Liang; Jing Li; Hangcheng Fu; Xinyang Liu; Peng Liu
Journal:  J Cancer       Date:  2019-08-27       Impact factor: 4.207

Review 8.  Receptor-defined subtypes of breast cancer in indigenous populations in Africa: a systematic review and meta-analysis.

Authors:  Amanda Eng; Valerie McCormack; Isabel dos-Santos-Silva
Journal:  PLoS Med       Date:  2014-09-09       Impact factor: 11.069

9.  Apolipoprotein A1 -75 G/A and +83 C/T polymorphisms and renal cancer risk.

Authors:  ZhiHong Liu; YingMing Xiao; LiangYou Tang; Liang Jiang; YuJie Wang; RuoChen Zhang; Qiang Wei; YiPing Lu
Journal:  Lipids Health Dis       Date:  2015-11-04       Impact factor: 3.876

10.  Single nucleotide polymorphisms of APOA1 gene and their relationship with serum apolipoprotein A-I concentrations in the native population of Assam.

Authors:  Kaustubh Bora; Mauchumi Saikia Pathak; Probodh Borah; Md Iftikar Hussain; Dulmoni Das
Journal:  Meta Gene       Date:  2015-11-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.